ANTI-FGFR2 ANTIBODY AND USE THEREOF

An anti-FGFR2 antibody, an encoding nucleic acid of the antibody, a vector and host cell for the expression and production thereof, an antibody-drug conjugate, and a pharmaceutical composition comprising the antibody. The present invention further relates to the use of the antibody molecule in a drug for diagnosing a cancer caused by FGFR2-pathway-related dysregulation, and the use of the antibody or antibody-drug conjugate in the preparation of a medicament for treating a cancer caused by FGFR2-pathway-related dysregulation, in particular gastric cancer..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 08. Nov. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

ZHU CHENGGANG [VerfasserIn]
XU LIANGLIANG [VerfasserIn]
DONG JIEXIAN [VerfasserIn]
ZHANG CHAOCHUN [VerfasserIn]
YANG XUAN [VerfasserIn]
PENG FANGLI [VerfasserIn]
LI YEQING [VerfasserIn]
CHEN CHAOLE [VerfasserIn]
BAO LIMING [VerfasserIn]
MIN XIANGYAN [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
C07K: Peptides (peptides containing β-lactam rings c07d; (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-11-08, Last update posted on www.tib.eu: 2024-04-09, Last updated: 2024-04-15

Patentnummer:

EP4273166

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA003138909